Detailed description page of THPdb

This page displays user query in tabular form.

Th1120 details

Primary information
ID 1556
ThPP ID Th1120
Therapeutic Peptide/Protein Name Teriparatide
Sequence Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification Ib
Molecular Weight 4117.715
Chemical Formula C181H291N55O51S2
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism Hepatic
Absorption Bioavailability is 95% following subcutaneous injection.
Volume of Distribution 0.12 L/kg
Clearance 62 L/hr [Women] 94 L/hr [Men]
Categories Bone Density Conservation Agents
Patents Number US6977077
Date of Issue 20/08/03
Date of Expiry 20/08/23
Drug Interaction N.A.
Target Parathyroid hormone/parathyroid hormone-related peptide receptor
Information of corresponding available drug in the market
Brand Name Forteo
Company Eli Lilly and Company
Brand Discription FORTEO (teriparatide [rDNA origin] injection) contains recombinant human parathyroid hormone (1-34), and is also called rhPTH (1-34). It has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone. Teriparatide has a molecular weight of 4117.8 daltons. Teriparatide (rDNA origin) is manufactured using a strain of Escherichia coli modified by recombinant DNA technology
Prescribed for Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture, Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture, Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture.
Chemical Name N.A.
Formulation Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge, pre-assembled into a delivery device, delivers 20 mcg of teriparatide per dose each day for up to 28 days.
Physcial Appearance Sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection
Route of Administration Subcutaneous
Recommended Dosage Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture. The recommended dose is 20 mcg subcutaneously once a day. Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture. he recommended dose is 20 mcg subcutaneously once a day.
Contraindication Hypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis
Side Effects N.A.
Useful Link http://en.wikipedia.org/wiki/Teriparatide, http://www.forteo.com/, http://www.rxlist.com/forteo-drug.htm,
PubMed ID 25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure Th1120 (View) or (Download)

Primary information
ID 1557
ThPP ID Th1120
Therapeutic Peptide/Protein Name Teriparatide
Sequence Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification Ib
Molecular Weight 4117.715
Chemical Formula C181H291N55O51S2
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism Hepatic
Absorption Bioavailability is 95% following subcutaneous injection.
Volume of Distribution 0.12 L/kg
Clearance 62 L/hr [Women] 94 L/hr [Men]
Categories Bone Density Conservation Agents
Patents Number US6770623
Date of Issue 09/12/02
Date of Expiry 09/12/22
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure Th1120 (View) or (Download)

Primary information
ID 1558
ThPP ID Th1120
Therapeutic Peptide/Protein Name Teriparatide
Sequence Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification Ib
Molecular Weight 4117.715
Chemical Formula C181H291N55O51S2
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism Hepatic
Absorption Bioavailability is 95% following subcutaneous injection.
Volume of Distribution 0.12 L/kg
Clearance 62 L/hr [Women] 94 L/hr [Men]
Categories Bone Density Conservation Agents
Patents Number CA2314313
Date of Issue 09/02/09
Date of Expiry 09/12/22
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure Th1120 (View) or (Download)

Primary information
ID 1559
ThPP ID Th1120
Therapeutic Peptide/Protein Name Teriparatide
Sequence Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification Ib
Molecular Weight 4117.715
Chemical Formula C181H291N55O51S2
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism Hepatic
Absorption Bioavailability is 95% following subcutaneous injection.
Volume of Distribution 0.12 L/kg
Clearance 62 L/hr [Women] 94 L/hr [Men]
Categories Bone Density Conservation Agents
Patents Number CA2325371
Date of Issue 18/08/08
Date of Expiry 20/08/23
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure Th1120 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1556
ThPP ID	Th1120
Therapeutic Peptide/Protein Name	Teriparatide
Sequence	Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	4117.715
Chemical Formula	C181H291N55O51S2
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease	For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics	Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action	Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity	Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism	Hepatic
Absorption	Bioavailability is 95% following subcutaneous injection.
Volume of Distribution	0.12 L/kg
Clearance	62 L/hr [Women] 94 L/hr [Men]
Categories	Bone Density Conservation Agents
Patents Number	US6977077
Date of Issue	20/08/03
Date of Expiry	20/08/23
Drug Interaction	N.A.
Target	Parathyroid hormone/parathyroid hormone-related peptide receptor
Information of corresponding available drug in the market
Brand Name	Forteo
Company	Eli Lilly and Company
Brand Discription	FORTEO (teriparatide [rDNA origin] injection) contains recombinant human parathyroid hormone (1-34), and is also called rhPTH (1-34). It has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone. Teriparatide has a molecular weight of 4117.8 daltons. Teriparatide (rDNA origin) is manufactured using a strain of Escherichia coli modified by recombinant DNA technology
Prescribed for	Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture, Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture, Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture.
Chemical Name	N.A.
Formulation	Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge, pre-assembled into a delivery device, delivers 20 mcg of teriparatide per dose each day for up to 28 days.
Physcial Appearance	Sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection
Route of Administration	Subcutaneous
Recommended Dosage	Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture. The recommended dose is 20 mcg subcutaneously once a day. Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture. he recommended dose is 20 mcg subcutaneously once a day.
Contraindication	Hypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis
Side Effects	N.A.
Useful Link	http://en.wikipedia.org/wiki/Teriparatide, http://www.forteo.com/, http://www.rxlist.com/forteo-drug.htm,
PubMed ID	25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure	Th1120 (View) or (Download)

Primary information
ID	1557
ThPP ID	Th1120
Therapeutic Peptide/Protein Name	Teriparatide
Sequence	Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	4117.715
Chemical Formula	C181H291N55O51S2
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease	For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics	Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action	Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity	Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism	Hepatic
Absorption	Bioavailability is 95% following subcutaneous injection.
Volume of Distribution	0.12 L/kg
Clearance	62 L/hr [Women] 94 L/hr [Men]
Categories	Bone Density Conservation Agents
Patents Number	US6770623
Date of Issue	09/12/02
Date of Expiry	09/12/22
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure	Th1120 (View) or (Download)

Primary information
ID	1558
ThPP ID	Th1120
Therapeutic Peptide/Protein Name	Teriparatide
Sequence	Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	4117.715
Chemical Formula	C181H291N55O51S2
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease	For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics	Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action	Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity	Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism	Hepatic
Absorption	Bioavailability is 95% following subcutaneous injection.
Volume of Distribution	0.12 L/kg
Clearance	62 L/hr [Women] 94 L/hr [Men]
Categories	Bone Density Conservation Agents
Patents Number	CA2314313
Date of Issue	09/02/09
Date of Expiry	09/12/22
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure	Th1120 (View) or (Download)

Primary information
ID	1559
ThPP ID	Th1120
Therapeutic Peptide/Protein Name	Teriparatide
Sequence	Parathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	4117.715
Chemical Formula	C181H291N55O51S2
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	Recombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/Disease	For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Pharmacodynamics	Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of Action	Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Toxicity	Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
Metabolism	Hepatic
Absorption	Bioavailability is 95% following subcutaneous injection.
Volume of Distribution	0.12 L/kg
Clearance	62 L/hr [Women] 94 L/hr [Men]
Categories	Bone Density Conservation Agents
Patents Number	CA2325371
Date of Issue	18/08/08
Date of Expiry	20/08/23
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D Structure	Th1120 (View) or (Download)